Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | 1 | Investing.com Deutsch | ||
08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 85 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 190 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 163 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
19.03. | Sera Prognostics appoints Jeff Elliott to board | 1 | Investing.com | ||
19.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
19.03. | Sera Prognostics GAAP EPS of -$0.25 misses by $0.01, revenue of $0.02M | 4 | Seeking Alpha | ||
19.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
19.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
11.02. | Sera Prognostics dips 5%, prices $50M offering | 3 | Seeking Alpha | ||
10.02. | Sera Prognostics announces proposed public offering | 3 | Seeking Alpha | ||
10.02. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
31.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 108 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
07.08.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 147 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NANOREPRO | 1,645 | -0,30 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,680 | -8,22 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
IBIO | 0,745 | +4,93 % | Pharos iBio Receives IND Approval for PHI-501 Phase 1 Trial | ||
REDHILL BIOPHARMA | 1,770 | -2,75 % | RedHill Biopharma Ltd. - F-1, Registration statement for certain foreign private issuers | ||
ARBUTUS BIOPHARMA | 2,670 | 0,00 % | Arbutus regains China rights to potential functional hep B cure as part of strategic rethink | ||
ALDEYRA | 3,246 | +0,65 % | Aldeyra-Aktie steigt nach FDA-Vereinbarung zum Krebsmedikament-Studiendesign | ||
MANNKIND | 3,214 | +0,19 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
CARDIFF ONCOLOGY | 2,695 | +0,56 % | Cardiff Oncology, Inc. - 8-K, Current Report | ||
TRAWS PHARMA | 1,430 | -100,00 % | Traws Pharma, Inc.: Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness | NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to... ► Artikel lesen | |
COHERUS ONCOLOGY | 0,643 | +1,42 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen |